1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Artificial Intelligence (AI) in Biotechnology Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Artificial Intelligence (AI) in Biotechnology Market, by Offering
8.1.1 Software
8.1.1.1. Market Revenue and Forecast
8.1.2. Hardware
8.1.2.1. Market Revenue and Forecast
8.1.3. Services
8.1.3.1. Market Revenue and Forecast
9.1. U.S. Artificial Intelligence (AI) in Biotechnology Market, by Applications
9.1.1. Drug Target Identification
9.1.1.1. Market Revenue and Forecast
9.1.2. Drug Screening
9.1.2.1. Market Revenue and Forecast
9.1.3. Image Screening
9.1.3.1. Market Revenue and Forecast
9.1.4. Predictive Modeling
9.1.4.1. Market Revenue and Forecast
10.1. U.S. Artificial Intelligence (AI) in Biotechnology Market, by Usage
10.1.1. Agriculture Biotechnology
10.1.1.1. Market Revenue and Forecast
10.1.2. Medical Biotechnology
10.1.2.1. Market Revenue and Forecast
10.1.3. Animal Biotechnology
10.1.3.1. Market Revenue and Forecast
10.1.4. Industrial Biotechnology
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Offering
11.1.2. Market Revenue and Forecast, by Applications
11.1.3. Market Revenue and Forecast, by Usage
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Offering
11.1.4.2. Market Revenue and Forecast, by Applications
11.1.4.3. Market Revenue and Forecast, by Usage
12.1. AstraZeneca
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Bristol-Myers Squibb
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Gilead Sciences, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Sanofi
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Abbott Laboratories
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Biogen
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Pfizer, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Novo Nordisk A/S
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Amgen, Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck KGaA
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
